Literature DB >> 12946833

The genetics of pancreatic cancer.

Sarah M Cowgill1, Peter Muscarella.   

Abstract

The genetic basis for invasive and preoneoplastic neoplasms of the exocrine and endocrine pancreas has been the subject of a number of investigations in recent years. The purpose of this paper was to briefly review and summarize the pertinent findings. High frequency changes associated with pancreatic adenocarcinomas include mutations of the k-ras oncogene, and inactivating alterations of the p53, p16, and DPC4 tumor suppressor genes. Hereditary syndromes that have a known predisposition for pancreatic adenocarcinoma development include hereditary pancreatitis, familial atypical multiple mole melanoma (FAMM) syndrome, Peutz-Jeghers syndrome, familial breast cancer (BRCA-2), hereditary nonpolyposis colorectal cancer syndrome (HNPCC), and Li-Fraumeni syndrome. The underlying genetic defects have been identified and are currently being studied. Germline mutations of the men-1 gene are responsible for the MEN-1 syndrome, known to be associated with pancreatic endocrine tumors. It appears that somatic mutations of the gene are present in at least a subset of sporadic tumors. In addition, alterations in the Rb/p16 pathway appear to be commonly associated with pancreatic endocrine tumors. Further characterization of pancreatic tumors will result in a better understanding of the cellular pathways involved in pancreatic tumorigenesis and holds promise to identify targets for novel diagnostic and therapeutic strategies.

Entities:  

Mesh:

Year:  2003        PMID: 12946833     DOI: 10.1016/s0002-9610(03)00226-5

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  45 in total

1.  Reverse correlation of Jab1 and Smad4 in PANC-1 cells involved in the pathogenesis of pancreatic cancer.

Authors:  Jun Li; Zhuoyu Gu; Siyuan Li; Zhiwei Xiao; Kan Sun
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

2.  Targeting reactive nitrogen species suppresses hereditary pancreatic cancer.

Authors:  Mo Li; Qian Chen; Teng Ma; Xiaochun Yu
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-19       Impact factor: 11.205

3.  Association of diabetes susceptibility gene calpain-10 with pancreatic cancer among smokers.

Authors:  Pui-yee Fong; Megan D Fesinmeyer; Emily White; Federico M Farin; Sengkeo Srinouanprachanh; Zahra Afsharinejad; Margaret T Mandelson; Teresa A Brentnall; Matt J Barnett; Gary E Goodman; Melissa A Austin
Journal:  J Gastrointest Cancer       Date:  2010-09

4.  Information recovery in cancer families: value for risk estimations.

Authors:  Hassan Roudgari; Lindsey F Masson; Neva E Haites
Journal:  Fam Cancer       Date:  2007-05-23       Impact factor: 2.375

5.  Construction of targeted plasmid vector pcDNA3.1-Egr.1p-p16 and its expression in pancreatic cancer JF305 cells induced by radiation in vitro.

Authors:  Hong-Bing Ma; Xi-Jing Wang; Zheng-Li Di; Hui Xia; Zheng Li; Jie Liu; Jie Ma; Hua-Fen Kang; Cong-Mei Wu; Ming-Hua Bai
Journal:  World J Gastroenterol       Date:  2007-08-21       Impact factor: 5.742

Review 6.  Pancreatic cancer: pathogenesis, prevention and treatment.

Authors:  Fazlul H Sarkar; Sanjeev Banerjee; Yiwei Li
Journal:  Toxicol Appl Pharmacol       Date:  2006-11-11       Impact factor: 4.219

7.  Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM).

Authors:  Asfar Sohail Azmi; Aamir Ahmad; Sanjeev Banerjee; Vivek M Rangnekar; Ramzi M Mohammad; Fazlul H Sarkar
Journal:  Pharm Res       Date:  2008-04-22       Impact factor: 4.200

Review 8.  Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform.

Authors:  J Wu; S Liu; J Yu; G Zhou; D Rao; C M Jay; P Kumar; R Sanchez; N Templeton; N Senzer; P Maples; J Nemunaitis; F C Brunicardi
Journal:  Cancer Gene Ther       Date:  2014-01-24       Impact factor: 5.987

Review 9.  Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?

Authors:  H G Smeenk; T C K Tran; J Erdmann; C H J van Eijck; J Jeekel
Journal:  Langenbecks Arch Surg       Date:  2004-05-14       Impact factor: 3.445

10.  Does Mutated K-RAS Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention?

Authors:  Photini F S Rice; Kevin G Ehrichs; Mykella S Jones; Hwudarw Chen; Chiu-Hsieh Hsu; Edward R Abril; Raymond B Nagle; David G Besselsen; Jennifer K Barton; Natalia A Ignatenko
Journal:  Cancer Prev Res (Phila)       Date:  2017-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.